Breaking news

EU Abolishes Duty-Free Exemption For Low-Value Parcels Ahead Of Customs Overhaul

by THEFUTURE.TEAM

November 15, 2025

The European Union is set to eliminate the duty-free exemption for parcels valued under €150, a measure that will reshape the competitive landscape of international e-commerce. Starting in early 2026, platforms like Temu and Shein could face significant adjustments as the reform takes effect.

Accelerated Timeline and Transitional Mechanism

Originally slated for mid-2028, the scrapping of the so-called de minimis threshold has been advanced, with EU finance ministers agreeing to implement a transitional system starting in the first quarter of 2026. The technical specifics, to be finalized at the upcoming Ecofin meeting on December 12, signal Brussels’ commitment to streamline customs controls ahead of a broader customs union reform.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Unintended Consequences of the Current Regime

Under the existing framework, goods imported into the EU valued below €150 enjoy exemption from customs duties—though VAT applies along with the requirement for a customs declaration. The European Commission notes that this policy has spurred a dramatic influx of small parcels, with 4.6 billion low-value items registered last year, 91 percent of which originated in China. This system has inadvertently skewed competition by enabling direct-to-consumer shipments that often bypass rigorous product safety, environmental standards, and checks for counterfeit goods.

New Customs Duties and Handling Fees

To level the playing field and bolster customs inspections, the EU is set to impose a new customs duty coupled with a handling fee on each small parcel. The Commission has proposed a flat fee of approximately €2 per item, although final determinations regarding the fee structure remain under discussion among member states. While some governments, such as France, are advocating rapid EU-wide implementation, alternatives including national surcharges are also under consideration.

Implications for Cyprus: A Paradigm Shift for Consumers and Retailers

For Cyprus, the modification represents a stark departure from current customs practices. The Cyprus Consumers’ Protection Service has underscored that while shipments from outside the EU currently benefit from duty exemptions on low-value parcels (subject to VAT and additional charges), these orders may face new hurdles including customs duties and potential delays from enhanced inspections.

Moreover, local businesses, which contend with the competitive pressures of e-commerce giants exploiting the existing de minimis loophole, could experience a realignment of the market dynamics. This change is expected to relieve some competitive strain as imported products begin to attract duties similar to bulk imports handled by traditional retailers.

Looking Ahead

As the legislative text moves towards final approval by the European Parliament, the EU’s decision underscores a broader strategy: to harmonize international trade practices, ensure compliance with stringent safety standards, and secure fair market competition. For consumers and businesses alike, the shift marks the beginning of a more regulated cross-border e-commerce environment, with the potential for higher consumer prices and altered supply chain dynamics.

The evolving policy landscape provides a telling example of how regulatory reforms can affect global markets. In an increasingly interconnected world, balancing innovation with regulatory oversight remains a critical challenge for policymakers and industry stakeholders.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.